

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
Otsuka Pharmaceuticals	All Wales Therapeutics and Toxicology
(donidalorsen)	Centre
	 Allied Health Professionals Federation
Patient/carer groups	 Board of Community Health Councils in
Allergy UK	Wales
Anaphylaxis Campaign	British National Formulary
Asthma and Lung UK	Care Quality Commission
Genetic Alliance UK	Department of Health, Social Services
HAE UK	and Public Safety for Northern Ireland
Immunodeficiency UK	Healthcare Improvement Scotland
NARA- The Breathing Charity	Hospital Information Services –
South Asian Health Foundation	Jehovah's Witnesses
Specialised Healthcare Alliance	Medicines and Healthcare products
UK Primary Immune-deficiency	Regulatory Agency
Patient Support Charity (UKPIPS)	National Association of Primary Care
Tation Support Shartly (Orti ii S)	National Pharmacy Association
Healthcare professional groups	NHS Confederation
Association for Respiratory	NHS Wales Joint Commissioning
Technology and Physiology	Committee
Association of Genetic Nurses &	Scottish Medicines Consortium
Counsellors	Welsh Government
Association of Paediatric Emergency	Weish Government
Medicine	Possible comparator companies
British Geriatrics Society	ADVANZ (tranexamic acid)
British Paediatric Allergy, Immunity	BioCryst Pharmaceuticals (berotralstat)
and Infection Group (BPAIIG)	
British Paediatric Respiratory Society	Bowmed Ibisqus (tranexamic acid) CSL Robring (Regional garadacimal)
British T aediatric Respiratory Society British Skin Foundation	CSL Behring (Berinert, garadacimab) Maywellia (transyamia asid)
British Society for Allergy & Clinical	Maxwellia (tranexamic acid)
Immunology	Mylan (tranexamic acid) Diagram (tranexamic acid)
British Society for Genetic Medicine	Pfizer (tranexamic acid) Pharming Crown N.V. (Purchase)
	Pharming Group N.V (Ruconest)
British Society for Haematology British Society for Immunology	Rivopharm (tranexamic acid)
British Society for Immunology British Thomasia Consists	Sovereign Medical (tranexamic acid)
British Thoracic Society	 Takeda (Cinryze, lanadelumab)

Provisional stakeholder list for the evaluation of donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457



Provisional Consultees Provisional Commentators (no right to submit or appeal) **BSI Clinical Immunology Professional** Tillomed Laboratories (tranexamic acid) Network (BSI-CIPN) ILD-IN: Interstitial Lung Diseases Relevant research groups Asthma, Allergy and Inflammation Interdisciplinary Network Research Trust Immunology and Allergy Nurses British Association for Lung Research Group National Heart and Lung Institute Cochrane Airways Group Neonatal and Paediatric Pharmacists David Hide Asthma and Allergy Research Centre Group Primary Care Respiratory Society UK Genomics England Royal College of General Practitioners MRC Clinical Trials Unit Royal College of Nursing National Institute for Health Research Royal College of Paediatrics & Child Associated Public Health groups Health **Public Health Wales** Royal College of Pathologists **UK Health Security Agency** Royal College of Physicians Royal Pharmaceutical Society Associated Public Health groups Royal Society of Medicine Public Health Wales Royal Society of Medicine - Allergy UK Health Security Agency and Immunology Section **UK Clinical Pharmacy Association** UK Forum on Haemoglobin Disorders **Others** Department of Health and Social Care NHS England

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

Issue date: April 2025



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.